Bowler I M, Kelman B, Worthington D, Littlewood J M, Watson A, Conway S P, Smye S W, James S L, Sheldon T A
Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds.
Arch Dis Child. 1995 Nov;73(5):427-30. doi: 10.1136/adc.73.5.427.
To assess the benefit of nebulised amiloride added to the standard inpatient treatment of a respiratory exacerbation in cystic fibrosis.
Prospective, randomised, double blind, placebo controlled trial.
27 cystic fibrosis patients (mean age 12.8 years).
Two hospitals in Leeds, UK.
Both forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. The time to reach peak FVC was significantly reduced in the amiloride group (4.2 v 7.6 days; 95% CI 0.4 to 6.4 days), but not in the time to reach peak FEV1 (5.7 v 7.9 days; 95% CI -1.2 to 5.6 days).
Amiloride did not result in a greater overall improvement in respiratory function. There was a suggestion that it may have an effect on the rate of improvement, and thus may possibly influence the duration of treatment. This hypothesis deserves further evaluation.
评估雾化用氨氯吡咪添加到囊性纤维化呼吸加重期标准住院治疗中的益处。
前瞻性、随机、双盲、安慰剂对照试验。
27例囊性纤维化患者（平均年龄12.8岁）。
英国利兹的两家医院。
在治疗过程中，一秒用力呼气容积（FEV1）和用力肺活量（FVC）均有改善，尽管在研究的三个时间段中的任何一个时间段，两组的呼吸功能均无差异。氨氯吡咪组达到FVC峰值的时间显著缩短（4.2天对7.6天；95%可信区间0.4至6.4天），但达到FEV1峰值的时间未缩短（5.7天对7.9天；95%可信区间-1.2至5.6天）。
氨氯吡咪并未使呼吸功能总体上有更大改善。有迹象表明它可能对改善速率有影响，从而可能影响治疗持续时间。这一假设值得进一步评估。
